Kornimate/medical-research-clean huggingface dataset:
ultrasound to evaluate the quadriceps muscle wasting

Conditions: Severe Cerebral Pathology

Summary: intensive care unit acquired muscle weakness (icuaw) is a common disease. after 7 days of mechanical ventilation, a quarter of patients develop an icuaw responsible of a 15-20% of muscle loss. this is a serious pathology associated with high morbidity and mortality. clinical diagnosis of icuaw is difficult and need a patient awoken. ct scan and magnetic resonance imaging (mri) are considered as "gold standards" to quantify and monitor changes in muscle mass. but these tools are not adapted to icu patients. ultrasound (us) is an easy access tool at the bedside to assess muscle mass and does not expose the patient to additional radiation. the objective of this study is to evaluate the correlation between us and ct scan to measure quadriceps muscle thickness of icu patients.

as part of the monitoring of the neurological disease, brain ct scans are frequently performed. at the same time, an acquisition sequence centered on the quadriceps will follow the brain sequences. up to three brain ct scans coupled with a quadriceps imaging will be performed between the day of admission and on the tenth day of hospitalization. an ultrasound of the quadriceps will be performed concomitantly. the thickness of the quadriceps is measured by an independent operator on ct and ultrasound images.

Eligibility criteria:
inclusion criteria: * patient over 18 years admitted to intensive care for a severe brain injury (glasgow \<8) and with a predictive duration of mechanical of at least 48hours exclusion criteria: * pregnancy, * bilateral trauma of thighs, * coma induced by poisoning or by a metabolic disorder, * morbid obesity (bmi \> 35).

Keywords: severe cerebral pathology ultrasound thickness of the quadriceps
effect of hypocaloric diet and exercise in obese women who are subjected to ivf cycle

Conditions: Obesity

Summary: the purpose of this study is to determine the impact of diet and physical exercise program on pregnancy rate and live birth in obese women who undergo an ivf cycle.

the objective of this study is showing that obesity significantly affects the in vitro fertilization cycles lowering the reproductive capacity. the study is been performed in hospital de la santa creu i sant pau and fundació puigvert of barcelona. patients recluted are obese women with sterility problems that require in vitro fertilization (ivf) with a body mass index bmi between 30-35. it´s a randomised study in which half of the patients undergo to a 6 weeks program of diet and exercice. we will analyse the response to ovaric stimulation, the results of the egg retrieval (ovocyte number and quality), rates of fecundation, embryo implantation and clinical gestation.

Eligibility criteria:
inclusion criteria: * women who want pregnancy. * basal fsh levels ≤ 10 iu / l. * infertility to justify treatment with ivf/icsi. * being included in a long protocol with gnrh agonist. * presence of both ovaries and uterus able to support embryo implantation and pregnancy. * body mass index (bmi) ≥ 30 kg/m2 and ≤ 35 kg/m2. * absence of pregnancy before starting ovarian stimulation. * having given their written consent. exclusion criteria: * female age ≤ 18 years and ≥ 35 years. * severe male factor not permit an ivf-icsi with ejaculated sample. * patients with low ovarian reserve (basal fsh levels ≥ 10 iu / l or lower antral follicle count to 6 follicles in both ovaries). * hiv seropositivity, hbv or hcv. * clinically important disease. * having frozen embryos from previous cycles of assisted reproduction. * unexplained vaginal bleeding. * poor response in previous ivf cycles with standard stimulation protocols * any contraindication to become pregnant. * known allergy to preparations of gonadotropins or its excipients. * high consumption of alcohol, drugs or psychotropic drugs. * concurrent participation in another study. * patients who have done previous cycles of ivf / icsi without success
inflammatory mediators and microrna analysis in premenstrual asthma

Conditions: Asthma

Summary: a small number of women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period. this study is being done to investigate the possible causes of this premenstrual increase in asthma symptoms and to help asthma care providers identify those patients who may suffer from this condition.

it is well established that women suffer more asthma symptoms and worse health-related quality of life than men with the same level of asthma severity. the etiology for these sex-related differences in unknown, but a subset of women has premenstrual asthma (pma) with worsening of their asthma symptoms either prior to or during menstruation. previous small trials have suggested that an increase in the host inflammatory response may correlate with pma symptoms. we have evidence that small inhibitory ribonucleic acids, micrornas, circulating in the peripheral blood of human patients may be expressed in different patterns in certain disease states when compared to healthy individuals. we plan to compare the patterns of microrna expression in a well characterized group of women with pma to those without pma to determine if alterations in these microrna patterns play a role in increased asthma symptoms in the premenstrual period. in addition, we plan to compare the levels of inflammatory markers in these populations to better define the specific subset of women that may be at risk for premenstrual asthma. by better characterizing these women, we hope to identify clinically relevant predictors that may guide therapy for women who suffer from pma. procedures to be used in this study include questionnaire administration, pulmonary function assessment, exhaled nitric oxide evaluation, urine sampling for pregnancy, and blood draws for microrna and serum leukotriene evaluation. these techniques are utilized widely in clinical asthma research, and are associated with minimal risk.

Eligibility criteria:
inclusion criteria: * diagnosis of asthma exclusion criteria: * are pregnant * take hormonal medication * have an illness with fever (\> 38.0 ˚ c or 100.4 ˚ f) within 24 hours of visit 1 or between visits 1 and 2 * are participating in another interventional research trial * have other major chronic illnesses that would interfere with participation * are taking the following medications: leukotriene receptor antagonists, oral steroids, anticoagulants, or insulin * are unable to provide consent

Keywords: premenstrual increase in asthma symptoms
stroke in young fabry patients (sifap2): characterization of the stroke rehabilitation

Conditions: Fabry Disease; Cerebrovascular Accident

Summary: new studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called fabry disease. in this case certain fat molecules are not digested and broken down by the body - but remain in the cells. these fat molecules build up to dangerous levels, which start to damage the body, because they accumulate e.g. in the walls of the blood vessels. this accumulation in the blood vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a stroke. the purpose of this study is to investigate the stroke rehabilitation of fabry patients during different therapeutic standard approaches for stroke and for fabry disease (if any). during this study, stroke patients with fabry disease will be monitored in greater detail to determine whether the differences in treatment are significant for patient recovery and on what they depend.

in a group of young stroke patients with diagnosed fabry disease the stroke rehabilitation will be investigated during different prophylactic therapeutic approaches. in this study the investigator will not be given any instructions on stroke and fabry therapy. all patients with any etiology of stroke and a diagnosed fabry disease submitted to the stroke unit of the participating centres which commit to work with the eusi (european stroke initiative) recommendations for stroke management and diagnosis will be included into the study.

Eligibility criteria:
inclusion criteria: * adult patients (18 - 55 years of age) with an acute cerebrovascular event (cve) of any etiology defined as patients having an ischemic stroke or transient ischemic attack * genetic diagnosis (a-galactosidase defect)of fabry disease * written informed consent from patient exclusion criteria: * no proven fabry disease * participating in an other clinical trial with any investigational new drug or medical device * contraindication to any of the diagnostic procedures like e.g. mri investigation * patient has been pretreated with enzyme replacement therapy at the date of informed consent of sifap2

Keywords: cerebrovascular accident cerebrovascular accident, acute fabry disease fabry's disease anderson-fabry disease cva (cerebrovascular accident) stroke, acute cerebral stroke
sounds for sleep study in patients suffering from moderate to severe insomnia

Conditions: Insomnia

Summary: assess the effect of a customized audio track delivered via standard commercially-available bone conduction headsets on the quality of sleep

a single-center study in 25 subjects suffering from moderate to severe insomnia and assess the effectiveness of the intervention. intervention consists of treatment using a customized audio track delivered via standard commercially-available bone conduction headsets daily for four (4) weeks. effectiveness is defined by a statistically significant improvement in insomnia severity index (isi) and pittsburgh sleep quality index (psqi) at baseline versus the end of the study.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * meets dsm 5 criteria for insomnia disorder * insomnia severity index (isi) of 15 - 28 exclusion criteria: * use of sleep medications, sedating or alerting medications or antidepressants in the last 3 months * diagnosis of any autoimmune disorder or any medical or sleep disorder that could affect sleep * pregnancy
safety study of a chinese herbal formula simotang oral liquid for the treatment of functional dyspepsia

Conditions: Functional Dyspepsia(FD) Was Studied; Effect of Simotang on FD Was Studied

Summary: functional dyspepsia (fd) is a common functional gastrointestinal disorder and is steadily becoming a public health problem.simotang is a classical formula that has been used to treat gastrointestinal disorders for hundreds of years \[9\] and was approved as an oral liquid drug by the chinese national food and drug administration in the 1980s.in this study,patients with functional dyspepsia were divided according to the inclusive criteria into treatment group and control group randomly, who were given simo decoction or domperidone tablets for 14 days。and then the gastric emptying, symptoms in plasma were observed before and after treatment in mult-center.


Eligibility criteria:
inclusion criteria: * patients met the definition of the rome iii criteria for fd exclusion criteria: -
vaccine hesitancy in patients with solid tumors: a cross-sectional single-center survey

Conditions: Cancer Patients; Vaccine-Preventable Diseases

Summary: cancer patients have a well-known and higher risk of vaccine-preventable disease (vpd) than the general population. vpd can cause serious complications due to compromised immune system, malnutrition and the same oncology treatments and represent a severe financial burden with a delay in treating the underlying cancer the main purpose of this survey is to analyse the perception of cancer patients on the topic vaccines and vaccine-preventable diseases, the acceptability of vaccines and the evaluation of the determining factors associated with the choice of the patient to be vaccinated or not. this information will be used to improve the management of these issues.


Eligibility criteria:
inclusion criteria: 1. \>18 years of age; 2. oncology patient defined as a patient with solid tumors undergoing active systemic treatment or follow-up; 3. written informed consent exclusion criteria: 1. patients with hematological tumors 2. patients who are unable to understand informed consent document
the effect of listening to surah al-inshirah on pain and anxiety after laparoscopic cholecystectomy surgery

Conditions: Patients of Laparoscopic Cholecystectomy

Summary: in the postoperative period, good pain and anxiety management is required to minimize complications and ensure recovery. patients should be evaluated with a holistic approach, taking into account factors such as physical and psychological discomfort, anxiety level, age, gender, previous pain level. pharmacological and non-pharmacological methods are used to relieve pain and anxiety in the postoperative period. non-pharmacological methods reduce the patient's pain and anxiety by creating a feeling of comfort and control in the patient. relaxation techniques such as hypnosis, yoga and music are among these. the main purpose of these methods is to draw the attention of the individual in another direction. praying is also one of the non-drug methods, and the number of studies on this subject is very limited, and there are studies where it has been determined that praying and praying reduces the anxiety levels of patients. purpose to examine the effect of listening to surah al-inshirah on pain and anxiety after laparoscopic cholecystectomy surgery. method the population of the study will consist of patients who have undergone laparoscopic cholecystectomy at mardin training and research hospital and kızıltepe state hospital, who meet the inclusion criteria and volunteer to participate in the research. the study group of 60 people who will participate in the research will be divided into two equal groups according to the table of random numbers obtained from the computer-based research randomizer program. experimental group patients; a patient descriptive characteristics form will be applied, pretest vas pain score and state anxiety scale will be applied. then, the surah al-inshirah will be listened to and the final test vas pain score and state anxiety scale will be applied. control group patients; a patient descriptive characteristics form will be applied, pretest vas pain score and state anxiety scale will be applied. the posttest vas pain score and state anxiety scale will be applied 10 minutes later, without any intervention.


Eligibility criteria:
inclusion criteria: * patients who can be contacted, * patients with an abdominal pain score of 4 and above as evaluated by vas after laparoscopic cholecystectomy surgery, * patients aged 18 and over were included in the study. exclusion criteria: * patients who can be contacted, * patients with an abdominal pain score of 4 and above as evaluated by vas after laparoscopic cholecystectomy surgery, * patients aged 18 and over were included in the study.

Keywords: laparoscopic cholecystectomy postoperative pain surah inshirah anxiety
schizophrenic patients taking part in integrated care program

Conditions: Schizophrenia; Schizoaffective Disorder; Schizophreni-form Disorder; Delusional Disorder; Psychotic Disorder Not Otherwise Specified

Summary: purpose of this non-interventional study (nis) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with seroquel for schizophrenia.


Eligibility criteria:
inclusion criteria: * outpatients suffering from schizophrenia, schizoaffective disorder, schizophreni-form disorder, delusional disorder or psychotic disorder not otherwise specified * age 18 - 65 years * current stable treatment with seroquel according to smpc since at least 2 months * given consent to take part in an integrated care program prior to study startwritten informed consent to take part in this nis exclusion criteria: * presence of any contraindication as described in the smpc * cancellation of participation in the integrated care program

Keywords: schizophrenia integrated care program seroquel
this is a dose-finding study followed by 2-year extension study to evaluate safety and tolerability of tinlarebant in adolescent subjects with stargardt disease

Conditions: Stargardt Disease

Summary: stargardt disease 1 (stgd1) is the most prevalent form of juvenile macular degeneration. it is caused by a rare, inherited autosomal recessive trait, leading to severe and irreversible blindness by the first or second decade of life. earlier onset of the disease is related to a rapid vision loss, while patients with a later onset tend to have a better prognosis. this study will enrol subjects aged 12-18 years old with a confirmed clinical diagnosis of stargardt disease type 1 (stgd1). this study will include 2 phases, the phase 1b portion is to determine the optimal dose for phase 2 based on the extent of retinol binding protein 4 (rbp4) reduction after 2 cycles of tinlarebant treatment. the phase 2 portion will evaluate the safety and efficacy of a single daily dose of tinlarebant over a 24-month treatment period.


Eligibility criteria:
major inclusion criteria: subject must have clinically diagnosed stargardt disease with at least one mutation identified in the abca4 gene. major exclusion criteria: any ocular disease other than stargardt disease at baseline that, in the opinion of the pi, would complicate assessment of a treatment effect.
sertraline and habit reversal in the treatment of patients with trichotillomania

Conditions: Impulse Control Disorders

Summary: the purpose of this study is to assess the extent of symptom remission in patients with trichotillomania following treatment with sertraline and/or behavior therapy.

the purpose of this study is to assess the extent of symptom remission in patients with trichotillomania following treatment with sertraline and/or behavior therapy. following entry into the study, subjects will undergo a washout period if they are currently taking a psychotropic medication (two weeks for psychotropic medications except for fluoxetine, which requires a four-week washout). subjects will then be given a single-blind placebo for two weeks and assessed for symptom consistency. subjects will take sertraline or placebo in a double-blind design. subjects will be assessed with the hamilton rating scale for depression (ham-d-17), beck depression inventory (bdi), beck anxiety inventory (bai), clinical global impressions scale (cgi), hair pulling scale (hps), trichotillomania (ttm) impact scale, psychiatric institute trichotillomania scale (pits), national institute of mental health (nimh) scale, and quality of life enjoyment and satisfaction questionnaire (q-les-q) at the start of the washout period and at the end of week two in order to be randomized into the study. subject randomization to a treatment arm will be based on the random table and in equal proportions. subject change scores will be assessed for the above scales, and change scores for the four different treatment groups will be assessed.

Eligibility criteria:
inclusion criteria: * patients will have a dsm-iv diagnosis of ttm. * ttm symptoms for at least 4 months. * scalp as primary site of hair pulling. * hps score greater than or equal to 15 or ttm impact scale score greater than 30. * written informed consent. * men or women aged 18-65 years old. * females of childbearing potential must have a negative serum beta-hcg pregnancy test. exclusion criteria: * pregnant women or women of childbearing potential who are not using a medically accepted means of contraception. * patients who, in the investigator's judgement, pose a serious suicidal or homicidal risk. * serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. patients on anticoagulant therapy. * history of seizure disorder. * comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder. * if there is a history of substance abuse, patients must be in remission at least 6 months. * past trials of sertraline. * currently being treated with behavioral therapy, specifically habit reversal training, for ttm. * other medications for medical disorders that may interact with sertraline.

Keywords: trichotillomania habit reversal training sertraline zoloft
effect of a cardiac rehabilitation program on chronic heart failure patients in yaoundé, cameroon

Conditions: Chronic Heart Failure (CHF)

Summary: careca-chf study is a non-randomized, prospective, single-arm study, enrolled ambulatory patients with stable chronic heart failure \[new york heart association (nyha) class ii/iii\]. patients will be followed-up during a period of 06-08 weeks. the aim of this study is to assess the effect of a cardiac rehabilitation program on patients with stable chronic heart failure in yaoundé, cameroon.

careca-chf study is a non-randomized, prospective, single-arm study, multicentric study. patients with stable chronic heart failure \[new york heart association (nyha) class ii/iii\] will be enrolled ambulatory. the program will take place during a period of 06-08 weeks. the aim of this study is to assess the effect of a cardiac rehabilitation program on patients with stable chronic heart failure in a resource-limited country.

Eligibility criteria:
inclusion criteria: * patients with stable chronic heart failure confirmed by a cardiac ultrasound and whose severity is rated stage ii or iii of nyha followed at yaoundé central hospital and yaoundé general hospital; * stable under treatment; * whose cardiac ultrasound is less than six months old; * having given his free and informed consent. exclusion criteria: * poor adherence to the cardiac rehabilitation program activities; * patients lost insight the program; * withdrawal of informed consent.

Keywords: cardiac rehabilitation chronic heart failure physical function cameroon
exercise training in patients with hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: exercise training (et) is highly beneficial in heart failure patients and has been suggested to confer significant symptomatic and functional improvements in patients with diastolic dysfunction. accordingly, the aim of this study was to examine the safety, feasibility of a structured et program in symptomatic hcm patients.


Eligibility criteria:
inclusion criteria: * hypertrophic cardiomyopathy * nyha 3 * maximal left ventricular wall thickness \> 20 mm * age \>18 exclusion criteria: * severe non-cardiac limitations of functional capacity such as neurological illness, lung disease, peripheral vascular or orthopedic problem, etc. * patients state post resuscitation for malignant ventricular arrhythmia. * history of effort induced syncope, complex ventricular arrhythmia or atrial fibrillation. * an exercise-induced decrease in blood pressure * severe left ventricular outflow obstruction defined as resting outflow gradient \> 50 mmhg on maximal therapy * atrial fibrillation with a poorly controlled ventricular response * advanced hypokinetic stage of hcm defined as lvef \< 40% * congestive heart failure of angina fc iv according to nyha or ccs respectively.

Keywords: hypertrophic cardiomyopathy exercise training cardiac rehabilitation heart failure